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Background: BTBD10 binds to Akt and protein phosphatase 2A (PP2A) and inhibits the PP2A-mediated dephos-
phorylation of Akt, thereby keeping Akt activated. Previous studies have suggested that BTBD10 plays an important
role in preventing motor neuronal death and accelerating the growth of pancreatic beta cells. Because levels of
BTBD10 expression are much lower in many non-nervous tissues than nervous tissues, there may be a relative of
BTBD10 that has BTBD10-like function in non-neuronal cells.
Results: A 419-amino-acid BTBD10-like protein, named KCTD20 (potassium channel tetramerization protein domain
containing 20), was to found to bind to all Akt isoforms and PP2A. Overexpression of KCTD20 increased Akt
phosphorylation at Thr308, as BTBD10 did, which suggests that KCTD20 as well as BTBD10 positively regulates
the function of Akt. KCTD20 was ubiquitously expressed in non-nervous as well as nervous tissues.
Conclusions: KCTD20 is a positive regulator of Akt and may play an important role in regulating the death and
growth of some non-nervous and nervous cells.
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Akt (three isoforms named Akt1-3 in mammalian cells)
plays an important role in promoting the survival of
many cells. Phosphatidylinositol 3-kinase is activated in
the growth factor-mediated signaling cascade, generat-
ing the secondary messengers phosphatidylinositol-3,
4-bisphosphate and phosphatidylinositol-3,4,5-trisphos-
phate (PIP3), which recruit Akt to the inner leaflet of
the cytoplasmic membrane. Akt, anchored to the mem-
brane via PIP3, is phosphorylated and activated by both
3-phosphoinositide-dependent kinase-1 (PDK-1)-mediated
phosphorylation of Akt at Thr308 and PDK-2 (or Ser473
kinase)-mediated phosphorylation of Akt at Ser473. Acti-
vated Akt subsequently phosphorylates and activates
downstream target proteins, thereby promoting cell sur-
vival [1,2].
An insufficiency of the Akt signaling has been
assumed to contribute to the pathogenesis of various
human diseases, including neurodegenerative diseases,
stroke, cancer, and diabetes [1-6]. In amyotrophic
lateral sclerosis (ALS), a representative motor-neuron-* Correspondence: sakimatu@tokyo-med.ac.jp
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distribution, and reproduction in any mediumspecific neurodegenerative disease, levels of Akt phospholy-
lation have been reported to be diminished, which may lead
to motor neuronal death [7,8].
BTBD10 is a unique Akt activator [9]. It activates Akt
by binding to both Akt and PP2A and by inhibiting
PP2A-mediated dephosphorylation of Akt. Overexpres-
sion of BTBD10 increases Akt phosphorylation, whereas
loss-of-function of BTBD10 decreases Akt phosphoryl-
ation in neuronal and pancreatic beta cells. Consequently,
overexpression of BTBD10 inhibits neuronal death
caused by expression of a familial ALS-linked gene
G93A-superoxide dismutase 1 (SOD1) [9]. Another
study has shown that overexpression of BTBD10 (also
named glucose metabolism-related protein 1) promotes
the growth of pancreatic beta cells, whereas knockdown
of endogenous BTBD10 expresion decreases high glucose-
induced cell proliferation and insulin-stimulated Akt
phosphorylation [10]. The level of BTBD10 expression is
reduced in motor neurons in spinal cords of sporadic ALS
patients [11] where TDP-43 aggregates are formed [12].
Disruption of the btbd-10 gene has been shown to cause
loss of motor neurons and impairment of motor perform-
ance in Caenorhabditis elegans [11]. These results suggest
that reduction of BTBD10 expression may contribute toCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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expression has been shown to be downregulated in a rat
intracerebral hemorrhage model [13].
Because the levels of BTBD10 expression are much
lower in many non-nervous tissues than nervous tissues
[9], there may be a relative of BTBD10 that has BTBD10
function in non-neuronal cells.
In the current study, we investigated KCTD20 (potas-
sium channel tetramerization protein domain containing
20), an isoform of BTBD10 [14]. Similar to BTBD10,
KCTD20 was found to associate with all Akt isoforms
and PP2A and upregulate its phospholylation level at
Thr308.Figure 1 Comparison in the amino acid sequence between BTBD10 a
acid sequences of human BTBD10 and human KCTD20 were aligned by Clu
that are strongly similar or weakly similar are shown by green or blue char
were subjected to SDS-PAGE, followed by immunoblot analysis using anti-KResults
KCTD20 is a relative of BTBD10
The gene encoding 419-amino-acid human KCTD20 is
located in chromosome 6, while that encoding 475-
amino-acid human BTBD10 is in chromosome 11. The
overall similarity in the amino acid sequence between
human BTBD10 and KCTD20 is 81.4% (Figure 1A). The
C-terminal 330-amino-acid region of BTBD10 is respon-
sible for the binding of BTBD10 to Akt [9]. The similar-
ity in the amino acid sequence between the C-terminal
330-amino-acid regions of BTBD10 and KCTD20 is
91.4% (296/324) (Figure 1A). The KCTD20 gene is
highly conserved among different mammalian species.nd KCTD20 and KCTD20 expression in mouse tissues. A, Amino
stalW. Identical residues are shown by red characters while residues
acters, respectively. A dash (−) means the gap. B, Mouse tissue lysates
CTD20 antibody (upper panel) or anti-GAPDH antibody (lower panel).
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human [GenBank:NP_775833] and mouse [GenBank:
NP_080164] KCTD20 is 94% (amino acids were aligned
using BLAST2).
KCTD20 is ubiquitously expressed in mouse tissues,
including nervous tissues (Figure 1B). Compared with
BTBD10, levels of KCTD20 expression in non-nervous
tissues except testis, spleen, and colon, are equal to or
higher than those in nervous tissues.
KCTD20 interacts with Akt or a catalytic subunit of PP2A
BTBD10 binds to all Akt isoforms and upregulates their
phosphorylation by inhibiting their dephosphorylation by
PP2A [9]. GST-pulldown assays showed that KCTD20
was co-precipitated with GST-tagged Akt 1, 2 or 3 but not
with GST (Figure 2). KCTD20 also co-precipitated with
the GST-tagged catalytic subunit of PP1A and PP2A [9].Figure 2 Interaction between KCTD20 and Akt or a catalytic subunit o
GST-protein phosphatase catalytic subunit (B) and His-Xpress-KCTD20 were
N-terminally His-Xpress-tagged KCTD20. pEBG vectors encoded N-terminall
(PP1Ac), and the catalytic subunit of PP2A (PP2Ac)). The pEBG backbone vecto
sepharose beads were performed using the cell lysates. His-Xpress-KCTD2
phosphatase (B), was detected with anti-Xpress antibody (upper panel) aTheses results show that KCTD20 binds to all Akt iso-
forms, PP1A, and PP2A.
Overexpression of KCTD20 upregulates the level of Akt
phospholylation at Thr308
Based on the finding that KCTD20 interacts with all
Akt isoforms and catalytic subunits of protein phospha-
tases, we next examined the effect of overexpression of
KCTD20 on the level of Akt phosphorylation. NSC34
motor neuronal cells were transfected with an expres-
sion vector encoding BTBD10 or KCTD20. The level of
Akt phosphorylation at Thr308 was increased by over-
expression of BTBD10 as well as KCTD20 (Figure 3A)
and this result was reproduced in another identical ex-
periment (Figure 3B). In contrast, the level of Akt phos-
phorylation at Ser473 was not apparently upregulated
by KCTD20 (Figure 3A).f protein phosphatase in COS7 cells. A and B, GST-Akt (A) or
coexpressed in COS7 cells by transfection. pEF4/KCTD20 encoded
y GST-tagged proteins (Akt1, Akt2, Akt3, the catalytic subunit of PP1A
r (named vector) encoded GST. GST-pulldown assays with glutathione
0, co-precipitated with GST-Akt (A) or GST-catalytic subunit of protein
nd anti-GST antibody (lower panel).
Figure 3 KCTD20 upregulates the level of phospho-Akt in
NSC34 cells. A, NSC34 cells, transfected with pEF4-BTBD10,
pEF4-KCTD20, or backbone vector, were harvested at 48 hr after
transfection. The cell lysates were subjected to SDS-PAGE, followed
by immunoblot analysis with indicated antibodies. B, The same
experiment, shown in (A), was repeated.
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BTBD10 intracellularly localizes in cytoplasm and shows
a unique filamentous structure [9]. In the present study,
KCTD20 also localized in cytoplasm and had a filament-
ous structure (Figure 4A). To examine whether KCTD20
colocalizes with BTBD10, we coexpressed His-Xpress-tagged human KCTD20 and BTBD10 in COS7 cells and
immunostained them using Xpress and BTBD10 anti-
bodies. KCTD20 and BTBD10 colocalized in the same
filamentous structure (Figure 4B).
Expression of KCTD20 is not downregulated in motor
neurons in ALS mice
Decreased expression of BTBD10 has been suggested to
cause motor neuron death via the downregulation of the
level of phospho-Akt [11]. Immunohistochemical analysis
of frozen sections of mouse spinal cords with the KCTD20
antibody has shown that KCTD20 is expressed in motor
neurons in anterior horns of spinal cords (Figure 4C). In a
previous study [11], levels of BTBD10 expression were
found to be downregulated in motor neurons in the spinal
cords of G93A-SOD1 transgenic mice at advanced stages
of ALS. We therefore examined levels of KCTD20 expres-
sion in the same G93A-SOD1 transgenic mice. At an early
symptomatic stage (Day 60), the level of KCTD20 expres-
sion in G93A-SOD1 transgenic mouse motor neurons was
similar to that in motor neurons in wild-type littermates.
Although the level of BTBD10 expression was decreased
in motor neurons of G93A-SOD1 transgenic mice, com-
pared with that of wild-type littermates, at 120 days [11],
the level of KCTD20 expression was not decreased at
120 days or 140 days (Figure 4C).
Discussion
In the current study, we identified KCTD20, an isoform
of BTBD10, as a novel putative Akt or PP2A-interacting
protein. Based on the result that overexpression of
KCTD20 increased the level of Akt phosphorylation at
Thr308, it is highly likely that similarly to BTBD10,
KCTD20 positively regulates Akt (Figure 3). On the
other hand, overexpression of KCTD20 or BTBD10 did
not apparently increase the level of phosphorylation of
Akt at Ser473 (Figure 3). The previous study also
showed that overexpression of BTBD10 only weakly in-
creased the level of phosphporylation of Akt at Ser473
while it increased the level of phosphporylation of Akt at
Thr308 in a definitive manner [9].
Phosphorylation of Akt at Thr308 and Ser473 is
catalyzed by different kinases, i.e., PDK-1 and PDK-2 (or
Ser473 kinase), respectively [1,2]. Similarly, phosphatases
involved in the dephosphorylation of Akt at Ser473 may
be different from those required for dephosphorylation
of Akt at Thr308. The putative phosphatases of Akt
have been proposed to be PP2A [15] and PHLPP1 (or
PHLPP2) [16,17]. Zhuo et al. has recently reported that
CSTP1 is a specific phosphatase of Akt at Ser473 [18]. It
is possible that KCTD20 and BTBD10 may preferentially
interact with the phosphatase of Akt at Thr308.
Phosphorylations of Akt at both Thr308 and Ser473
are necessary for the full activation of Akt [1,2].
Figure 4 Intracellular localization of KCTD20 or expression level of KCTD20 in mouse spinal cord anterior horn. A, His-Xpress-KCTD20
was expressed in COS7 cells by transfection of pEF4-KCTD20 endocing HisXpress-tagged KCTD20. The backbone pEF4 vector was similarly
transfected as a negative control. Transfected cells were fixed with 4% paraformaldehyde and immunostained with anti-Xpress antibody as a
primary antibody and FITC-conjugated anti-mouse IgG antibody as a secondary antibody. The scale bar indicates 20 μm. B, COS7 cells were
transfected with pEF4-KCTD20 and pCAGGS-BTBD10 and fixed at 48 hr after transfection. The cells were immunostained with Xpress or BTBD10
antibody as a primary antibody and FITC-conjugated anti-mouse IgG antibody or TexasRed-conjugated anti-rabbit IgG antibody as a secondary
antibody, respectively. C, Frozen sections of spinal cords of G93A-SOD1-Tg mouse or wild-type littermate were immunostained with KCTD20
antibody. Rightmost pictures in each series (indicated as day 120 preabsorption) were immunostained using KCTD20 antibody, preabsorbed with
the antigen peptide. Areas, surrounded by dashed lines, represent spinal ventral horns. The scale bar indicates 50 μm.
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ation at Ser473 may be unnecessary for activation of the
majority of downstream Akt targets, such as TSC2,
GSK3, and the TORC1 effectors, S6K and 4E-BP1 but
necessary for FoxO1/3a [19,20]. Therefore, dysregulation
of the function of KCTD20 and BTBD10 may affect
many cellular processes by changing the phosphorylation
of Akt at Thr308.Akt may act as an inhibitor of neuronal apoptosis and
loss-of-function of Akt may contribute to the pathogen-
esis of ALS. In support of this hypothesis, it has been
shown that levels of phospho-Akt are decreased in
motor neurons of spinal cords of ALS [7,8], administra-
tion of IGF-1 or VEGF, which activates Akt, prolongs
the lifespan of ALS model mice [21], and VEGF-
deficient mice show an ALS-like phenotype [22].
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shown to be downregulated in motor neurons in sporadic
human ALS cases [11]. Notably, the level of BTBD10 ex-
pression is downregulated only in motor neurons that
contain TDP-43 aggregates [12]. In a previous study [11],
BTBD10 expression was also shown to be downregulated
in motor neurons in G93A-SOD1 mice at advanced ALS
stages. On the other hand, KCTD20 expression was not
downregulated in motor neurons in G93A-SOD1 mice at
advanced ALS stages (Figure 4). This finding suggests that
KCTD20 is not involved in the ALS pathogenesis in con-
trast to BTBD10. However, this needs to be confirmed by
examining whether KCTD20 expression is unchanged in
motor neurons in other ALS mouse models (e.g., mutant
TDP-43 transgenic mouse or FUS transgenic mouse) and
ALS patients.
Levels of KCTD20 expression in a majority of non-
nervous tissues were found to be equal to or higher than
those in nervous tissues (Figure 1B), whereas levels of
BTBD10 expression have previously been shown to be
much lower in the majority of non-nervous tissues than
nervous tissues [9]. This finding on tissue distribution
suggests that KCTD20 plays a major role as an Akt acti-
vator in these non-nervous as well as nervous tissues
and dysregulation of KCTD20 may be linked to diseases
involving these tissues. Detailed characterization of the
function of KCTD20 will serve as an important hint to
the understanding of Akt-related biological events.
Conclusions
KCTD20 is a novel positive regulator of Akt phosphoryl-
ation at Thr308. KCTD20 may be involved in cellular
process via Akt in non-nervous and nervous tissues.
Methods
Cell culture
COS7 cells or motor neuronal cell NSC34 cells were cul-
tured in Dulbecco’s modified Eagle’s medium (Wako Pure
Chemical Industries, Osaka, Japan) supplemented with
10% fetal bovine serum (Hyclone, Logan, UT, USA).
Antibodies
A rabbit polyclonal antibody to mouse KCTD20 was gener-
ated by immunization with a synthetic peptide, LNAPLSQ
MAPNDFQD, corresponding to the C-terminal 15-amino-
acid peptides of mouse KCTD20, conjugated to Keyhole
Limpet Hemocyanin (Sigma-Ardrich, Saint-Louice, MO,
USA). Phospho-Akt (Thr308) (#4056), phospho-Akt
(Ser473) (#4060), Akt (#9272), or GAPDH were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA). Anti-Xpress antibody or anti-actin antibody was
purchased from Invitrogen (Carlsbad, CA, USA) or
SIGMA (St. Louis, MO, USA), respectively. Anti-GST
monoclonal antibody was purchased from UpstateBiotech (Charlottesville, VA). HRP-conjugated anti-
mouse IgG antibody or anti-rabbit IgG antibody,
used as the secondary antibody, was purchased from
Bio-Rad (Hercules, CA).
Plasmids
Human KCTD20 cDNA was obtained from human testis
cDNA (BioChain, Newark, CA, USA) using a primer set, a
sense primer 5′-CGGGATCCATGAATGTTCACCGTGG-
CAG-3′ and an antisense primer 5′-CGAATTCCTAATCC
TGAAAGTCGTTAGAAGC-3′. Mouse KCTD20 cDNA
was amplified by RT-PCR (High-fidelity RT-PCR kit,
Takara) using total RNA isolated with ISOGEN (Wako)
from NSC34 cells with a sense primer 5′-CGGGATCCAT
GAATGTTCACCAGGGCAG-3′ and an antisense primer
5′-GGAATTCCTAATCTTGAAAGTCATTCGGAGC-3′.
The cloned cDNAs were subcloned into pEF4 His-
Xpress vector at a cloning site BamHI/EcoRI. The plas-
mids encoding the catalytic subunit of PP1A (PP1Ac),
the catalytic subunit of PP2A (PP2Ac), Akt, or BTBD10
were constructed, as described previously [9].
GST-pulldown assay
COS7 cells, seeded onto 60-mm dishes, were transfected
with expression vectors by LipofectAMINE (Invitrogen)
and Plus reagent (Invitrogen) following the manufac-
turer’s protocol. The transfected cells were harvested at
48 hr after transfection and lysed with a lysis buffer
[20 mM HEPES (pH 7.5), 150 mM NaCl, 1 mM dithio-
threitol, 1 mM EDTA, 0.5% Triton X-100, and protease
inhibitor cocktail] by pipetting and sonication. After
centrifugation, the supernatants were precleared using
sepharose 4B beads (GE Healthcare Bio-Sciences Corp.,
Piscataway, NJ) for 7 hr followed by GST-pulldown
using glutathione beads (GE Healthcare Bio-Sciences
Corp.). The pulled-down beads were washed five times
with protease inhibitor free lysis buffer and subjected to
SDS-PAGE followed by immunoblotting with anti-Xpress
antibody or anti-GST antibody.
Immunohistochemistry
Frozen sections of spinal cords from G93A-SOD1 trans-
genic miceor wild type littermates were immunostained
with KCTD20 antibody as a primary antibody (0.01 mg/ml)
and FITC-conjugated anti-rabbit IgG antibody as a second-
ary antibody (1:200).
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